Fluoroquinolone use and valvular heart disease: is the jury still out?
Eur Heart J
.
2021 Aug 7;42(30):2909-2911.
doi: 10.1093/eurheartj/ehab426.
Authors
Juan Tamargo
1
,
Stefan Agewall
2
Affiliations
1
Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto Gregorio Marañón, 28049 Madrid, Spain.
2
University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
PMID:
34254116
DOI:
10.1093/eurheartj/ehab426
No abstract available
Publication types
Editorial
Comment
MeSH terms
Fluoroquinolones* / adverse effects
Heart Valve Diseases* / chemically induced
Heart Valve Diseases* / epidemiology
Humans
Substances
Fluoroquinolones